Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells

Leukemia

Volumn 11, Issue 9, 1997, Pages 1516-1522

  Zhou, D C ^a   Simonin, G ^a   Faussat, A M ^a   Zittoun, R ^a   Marie, J P ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔTEL DIEU   (France)

Author keywords

Acute myelogenous leukemia; Modulator; Multidrug resistance

Indexed keywords

DAUNORUBICIN; GLYCOPROTEIN P; IDARUBICIN; MITOXANTRONE; RHODAMINE 123; TETRAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; VERAPAMIL;

ACUTE LEUKEMIA; ARTICLE; ASSAY; BLOOD GROUP AB; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030809612     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400761     Document Type: Article

References (26)

1. Hunault M, Zhou DC, Delmer A, Ramond S, Viguié F, Cadiou M, Perrot JY, Levy V, Rio B, Cymbalista F, Zittoun R, Marie JP. Multidrug resistance (MDR1) gene expression in acute myeloid leukemia: major prognosis significance for the in vivo drug resistance to induction treatment. Ann Hematol 1997; 74: 65-71.
2. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
3. Endicott J, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 1989; 58: 137-171.
4. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kruz EU, Duncan AMV, Deeley RG. Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
5. Grant C, Valdimarsson G, Hipfner D, Almquist K, Cole S, Deeley R. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
6. Tsuruo T, Iida H, Tsukagoshi S, Sakuri Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastin by verapamil. Cancer Res 1981; 41: 4403-4412.
7. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 156-199.
8. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Phase I trial of etoposide with cyclospirine as a modulator of multidrug resistance. J Clin Oncol 1992; 10: 1624-1634.
9. Marie JP, Bastie JN, Coloma F, Faussat AM, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia. Leukemia 1993; 7: 821-825.
10. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11: 1652-1660.
11. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MM, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
12. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboximide derivative. Cancer Res 1993; 53: 4595-4602.
13. den Ouden D, van den Heuvel M, Schoester M, van Rens G, Sonneveld P. In vitro effect of GG120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia 1996; 10: 1930-1936.
14. Zhou DC, Ramond S, Viguié F, Faussat AM, Zittoun R, Marie JP. Progressive resistance to homoharringtonine in human myeloleukemia K562 cells: relationship to sequential emergence of MRP and MDR1 gene overexpression and MDR1 gene translation. Int J Cancer 1996; 65: 365-371.
15. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9: 1661-1666.
16. Marie JP, Faussat-Suberville AM, Zhou DC, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1992; 7: 825-832.
17. Kuffel MJ, Ames MM. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR 1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol 1995; 36: 223-226.
18. Ludescher C, Eisterer W, Hilbe W, Hofmann J, Thale RJ. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol 1995; 91: 652-657:
19. Baines P, Limaye M, Hoy T, Padua RA, Whittaker J, AI-Sabah A, Burnett A. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukemic blasts and in normal blood and marrow populations. Leukemia Res 1994; 18: 683-691.
20. te Boekhorst PAW, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Löwenberg B, Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157-3162.
21. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/effIux- cases. Blood 1995; 86: 2329-2342.
22. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer SA. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil and cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82: 1288-1299.
23. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 1996; 2: 7-12.
24. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995; 1: 578-582.
25. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
26. Marie JP. P-glycoprotein in adult hematological malignancies. Hematol/Oncol Clin N Am 1995; 9: 239-250.